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1* Comparison of bioinformatics, reporter minigene and mRNA study
to analyse the effect of unclassiﬁed variants on CFTR mRNA
splicing
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The CFTR gene is one of the most highly mutated human genes with more than
1600 different mutated alleles reported, and besides the most frequent mutations,
the deleterious effect of many variations remains unclear, which sometimes confuse
molecular geneticists, particularly for intronic or exonic silent variations, which can
affect mRNA splicing.
Several softwares have been developed for in silico prediction of the impact
of sequence variation on splicing, and they are commonly used in molecular
laboratories. But even if they have proven their effectiveness for many genes, it
is important to conﬁrm by in vitro functional analysis.
The aim of our study is to compare the bioinformatic predictions to results obtained
with a reporter minigene and by direct analysis of mRNA from patients.
On the basis of the bioinformatic predictions, more than 50 variations have been
classiﬁed into four classes according to the expected effect on mRNA splicing
(complete or partial exon exclusion, cryptic alternative splicing site, or no effect).
Two variations from each class were tested in our minigene vector and at the mRNA
level.
As expected, mutations affecting consensus donor splice lead to complete exon
exclusion and frequent polymorphisms located in the last nucleotides of exons did
not affect mRNA splicing.
More interestingly, some mutations, initially classiﬁed as splice mutations because
of their location on the acceptor sites yielded an unexpected result in bioinformatics
predictions, which was conﬁrmed by minigene and mRNA analysis.
This reporter minigene study will be extended to the 50 variations selected, and in
cases of discrepancy, analysis of mRNA will be performed.
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The mRNA analysis has evidenced to be an efﬁcient tool to detect mutations
disrupting the normal splicing process in genetic disorders. So far, CFTR gene
scanning and the large rearrangements study have allowed us to raise a detection
rate around 97% in the CF Spanish population. Currently, we have evaluated the
systematic analysis of CFTR RNA to improve this percentage. For this purpose
we have collected nasal epithelial cells from patients and controls and we have
developed ﬁve PCRs to cover the complete RNA using primers already described
and/or speciﬁcally designed (Primer3 v.0.4.0). The fragments size for a normal
transcript ranges from 600 bp to 1100 bp. In this preliminary study we have included
splicing mutations and large rearrangements leading to known aberrant transcripts as
well as missense mutations potentially involved in a reduction of the wild type CFTR
transcripts. In silico analysis has been also performed with the Alamut® software
v.1.5 to support the pathogenic effect of the mutations. Once the protocol conditions
have been optimized we are carrying out the RNA analysis in two different groups,
(a) CF samples partial/total uncharacterized to identify the unknown mutations; and
(b) sequence variants found in our population to assess their pathologic effect. We
believe the implementation of the RNA analysis will contribute to identify novel
molecular defects and mechanisms concerning the wide spectrum of the CF. Results
will be discussed.
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The great allelic heterogeneity in Cystic Fibrosis encourages the diagnostic appli-
cation of methods for the rapid screening of mutations.
In our Lab we have adopted DHPLC as enlarged mutation screening method,
following the search of the most frequent molecular defects.
Based on our experience, the reasons for the request of this deeper investigation
are:
1. CF Clinical diagnosis, typical or atypical, where only one or none mutations
have been identiﬁed by searching the most frequent molecular defects.
2. Male infertility, with suspicion of CBAVD
3. Family History of Cystic Fibrosis, without molecular characterization of the
proband
4. Partner heterozygous for a pathogenetic mutation of the CFTR gene.
The last group constitutes more than 75% of the requests we currently receive for
DHPLC from many regional and national Centres.
Since the end of 2006, we have analyzed 481 subjects, of which 376 with partner
carrier of Cyctic Fibrosis.
Of them, 41 were heterozygous for a rare pathogenetic mutation, with a frequency
of about 10%, three times higher than in general population.
Also in some cases of echogenic bowel, when the ﬁrst analysis revealed one of the
partner as a carrier of Cystic Fibrosis, we performed DHPLC in the second one (if
the gestational age allowed it). We have analyzed 124 couples with hyperechogenic
bowel: 6 were constituted by two CF carriers (4 of them identiﬁed by DHPLC).
The subsequent investigation on foetal DNA conﬁrmed the status of compound
heterozygous for two CFTR mutations, compatible with the clinical diagnosis of
Cystic Fibrosis.
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Search for CF mutations of frequency >1% according to geographic/ethnic origins
of individuals is a European recommendation (Dequeker et al., Hum Mutat 2009).
Given heterogeneity of populations living in European countries, additional search
for mutations speciﬁc of ethnicities by using sequencing, beside the use of a
common kit, is time-consuming and regularly leads to identiﬁcation of unknown
variants. Such variants make genetic counselling delicate, in particular when found
in CF carriers’ partners and cases of foetal bowel anomalies. There was thus a need
for tests focused on speciﬁc mutations.
We developed simple assays targeted on 6 geographic origins (Italy, Spain, Portugal,
Turkey, North Africa and Black Africa), containing 3−8 mutations and based on
probe hydrolysis during PCR and ﬂuorescence detection (custom TaqMan® SNP
genotyping). Homozygous and heterozygous mutant controls were generated from
cloned PCR products for each mutation. Validation was made on blind series of
DNA representative of different genotypes and on prospective series of patients’
DNAs to be tested in routine analysis, in comparison with sequencing.
The results fulﬁlled the validation requirements in terms of sensitivity, speciﬁcity,
repeatability, robustness and measurement uncertainty. These assays are simple and
rapid to implement in routine practice and simplify genetic counselling.
